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Sickle cell disease (SCD) is a blood disorder that is inherited from both parents and 
affects millions of people globally. The symptoms of SCD may be debilitating and pose a 
significant challenge to nursing care. Hydroxyurea (HU), the Food and Drug 
Administration (FDA) approved treatment for SCD in adults is reportedly effective, but 
its usage is still minimal among adolescents with SCD. The purpose of this systematic 
review was to evaluate existing literature on the barriers to HU use in adolescents with 
SCD. The Johns Hopkins Nursing Evidence-based Practice (JHNEBP) Rating Scales 
guided this study. An extensive electronic search of Cumulative Index to Nursing and 
Allied Health (CINAHL), MEDLINE, Your Journal OVID, Academic search premier, 
and Cochrane Database of Systematic reviews of articles published in English from 2003 
to 2013 was conducted.  The 5 articles that met the inclusion criteria were organized, 
tabulated, and analyzed. The results suggest that inadequate knowledge about HU; 
physician concern about carcinogenic potential; lack of awareness of the National Heart, 
Lung, and Blood Institute (NHLBI) recommendations on HU use; and lack of belief in 
the benefits of HU contribute to providers’ under-prescribing and minimal usage of the 
treatment.  The implications for social change include knowledge useful for SCD 
patients, parents/guardians, care providers, and other researchers who are searching for 
direction in improving the quality of life of SCD patients. Long-term results may include 
increased HU usage, decreased pain episodes, fewer emergency room visits, and reduced 
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Section 1: Nature of the Project 
Introduction 
Sickle cell disease (SCD) is an autosomal recessive genetic blood disorder related 
to different kinds of defective hemoglobin (Hb) especially common among people with 
ancestral background from sub-Saharan Africa, South America, the Caribbean, Saudi 
Arabia, Turkey, Greece, and Italy (Centers for Disease Control and Prevention [CDC], 
2014).  Presently, researchers have identified more than 700 structural hemoglobin 
variants, but only three hemoglobins (Hb) S, C, and E) are widespread. Sickle cell disease 
is characterized by series of severely painful, recurrent episodes that result from 
occlusions of small blood vessels leading to frequent emergency room visits. Infections, 
damage of organs, stroke, and other complications are also common (Ballas, 2010). To 
date, SCD treatment has been symptomatic with a focus on pain relief with opioids. 
However, hydroxyurea (HU), the only Federal Drug Administration FDA approved 
breakthrough in the pharmacotherapy of SCD within the past 20 years, is reportedly 
capable of modifying the disease pathogenesis, transforming the treatment of sickle cell 
disease (Neville & Panepinto, 2011). 
Despite reports that HU can decrease incidences of painful crises, is effective in 
treating acute chest syndrome, priapism, and increased levels of fetal hemoglobin (HbF) 
and reduces overall mortality rates in adult patients (Charache et al., 1995; Halsey & 
Robert, 1995; Saad et al., 2004; and Steinberg et al., 2003), there continues to be minimal 
use of HU in the management of sickle cell disease.  The aim of this project was to 
perform a systematic review of the literature on the barriers that prevent adolescents aged 
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12-18 from being compliant with HU.  According to the CDC (2014), the impact of SCD 
is not only on the patient but also on the family and society as a whole. The result of this 
systematic review will be used to recommend a rigorous education program on the effects 
of HU and to inform patients, their relatives and providers.  
Background of Sickle Cell Disease 
Sickle cell disease is an autosomal recessive blood disorder, meaning that the 
defective gene is on one of the first 22 pairs of chromosomes that do not ascertain gender. 
As such, SCD affects men and women equally. Getting one copy of the gene from each 
parent is essential to have the condition; as such, an individual with Hgb SS has acquired 
the genetic trait for SCD sickle cell disease hemoglobin S (HbS) from both parents 
(Myers & Eckes, 2012).  
There are three types of genotypes. Healthy individuals have genotype which is 
the normal hemoglobin (Hb ) AA, unaffected “carriers” have genotype hemoglobin (Hb) 
AS and are said to have the trait, and those with sickle cell disease have hemoglobin (Hb) 
SS. If two individuals with HbAS genotypes have children, one child will have a 25% 
chance of being healthy with HbAA. One child will have a 25% chance of having sickle 
cell anemia with HbSS genotypes. Two children will have a 50% chance of being an 
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Figure 1. Distribution of hemoglobin genotypes. 
Other forms of sickle cell disease can also occur if HbS is inherited from one 
parent and abnormal hemoglobin (for instance hemoglobin C (HbC) or thalassemia β is 
inherited from the other parent. This will give rise to HbSC or HbSβ respectively. The 
abnormality in the hemoglobin molecule results from mutation in the β-globin gene 
where a single nucleotide adenine to thymidine (A to T) in codon for amino acid 6. The 
change converts a glutamic acid codon (GAG) to a valine codon (GTG) (Cao, 2004). HbS 
has a unique property of causing polymerization (cellular aggregation) which changes 
normal red blood cells from smooth, round (like the letter “O”), and flexible state into a 
rigid, sticky, sickle-shaped cell (like letter “C”), causing clustering. This change makes 
movement in the blood vessels difficult. The cluster eventually leads to vaso-occlusion 
AS AS 
AA AS AS 
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and, as a result: pain crisis, tissue damage, susceptibility to serious infection, and organ 
failure (Cao, 2004; Ellison, 2007).  
In the past, treatment of SCD was mainly symptomatic, with a focus on pain relief 
using opiates.  Hydroxyurea (HU), the only FDA approved medication for SCD has been 
reported to reduce the damaging effect of SCD and improved some aspects of quality of 
life of the patients; however, its usage remains minimal (National Institutes of Health 
[NIH], 2008).  
The purpose of this project was to carry out a systematic review of evidence 
concerning existing practices related to the barriers that are preventing this patient 
population from complying with this promising treatment. As a result of the findings, an 
educational program will be recommended to improve community knowledge concerning 
HU, which will make patients and their relatives’ educated consumers. 
Problem Statement 
In the last 100 years, the treatment of SCD has focused on pain management with 
opioids, and folic acid for increasing fetal hemoglobin (HbF) which according to Ware 
(2010) is protective against clinical severity. Ware noted that low-percentage of HbF is 
linked to a higher risk of developing vaso-occlusive complications, organ damage, and 
early dearth. Neither of the early treatment approaches have had a significant impact in 
decreasing the crisis pain associated with SCD. Other treatments include blood 
transfusion and other palliative unapproved drugs.   
Several studies reported the effectiveness of HU and showed significant results in 
increase fetal hemoglobin level, decreases in the frequency of painful attacks, decreases 
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in the number of emergency room visits, decreases in hospitalizations, and improved 
health-related quality of life (Al-Nood, Al-Khawlani, & Al-Akwa, 2011; Ballas et al., 
2006; Charache et al., 1992; Panepinto, 2012).  
The effectiveness of HU was noted even at low doses; the medication still 
appeared to raise fetal hemoglobin levels in sickle cell patients (Al-Nood, Al-Khawlani, 
& Al-Akwa, 2011), but this medication continued to be met with resistance. A systematic 
review of literature examined the different barriers that are preventing adolescents ages 
12 – 18 with SCD from complying with HU. The review has identified barriers that 
prevent patients with sickle cell disease from being compliant with HU. Nurses are suited 
to provide health promotion in addressing this concern.  Furthermore, the advanced 
professional nurse is equipped to provide education for patients and their families.    
Purpose and Project Objective 
The purpose of this project was to review and disseminate knowledge regarding 
the barriers that prevent adolescents ages 12-18 with SCD from being compliant with HU 
therapy. Additionally, this systematic review also recognized the stigma associated with 
HU and the lack of knowledge concerning the decreased use of HU in the SCD 
population  
PICOT question 
To examine the evidence, formulation of the clinical issue must be presented in a 
searchable and answerable question using the patient population (P), intervention or issue 
of interest (I), comparison intervention (C), status-outcome (O), and the time frame (T) 
for the intervention to achieve the outcome, in the (PICOT) format.  The clinical question 
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was formulated in a structured and specific way to assist the reviewer in finding the 
appropriate evidence to answer the questions and decrease bias (Melnyk & Fineout-
Overholt, 2011).   The patient or population to whom the question applies for this review 
is adolescents ages 12-18 with SCD. The intervention or issue being considered is the 
barriers that prevent adolescents with SCD from being compliant with HU?  The PICO 
question that guided this review was: what are the barriers that prevent adolescents ages 
12 – 18 with SCD from being compliant with HU? 
Frameworks for the Project 
I used the JHNEBP for this systematic review of the literature. This evidence-
based appraisal guide is a comprehensive manual that provides a novice or advanced 
nurses with specific guidelines about evidence-based practice (Newhouse, Dearholt, Poe, 
Pugh, & White, 2007). It further detailed a step by step appraisal on how to critique 
evidence-based studies and rating scales which provided information regarding the 
quality and strength of evidence used. This manual has a wealth of scholarly authors who 
are experts in the field of evidence-based practice. 
This framework provided the basis for the analysis of evidence available on the 
barriers preventing SCD patients from using HU. This was achieved by using the model’s 
application process of practice question, evidence, and translation (PET).  This evidence-
based practice (EBP) process conceptualizes asking a practice question, finding evidence, 
and translating the evidence into practice. It therefore, laid the foundation for gathering 
and assessing additional evidence that was revealed by following the specific steps of the 
application process. The JHNEBP model is a manual that has been referenced globally 
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for its succinct overview of EBP as well as providing an in-depth and broad structure that 
is comprehensive and user-friendly. 
Nature of the Doctoral Project 
A systematic review of the literature was carried out in an attempt to meet the 
project goals of identifying the barriers that prevent SCD patients from being compliant 
with HU. It also addressed stigma, lack of knowledge concerning treatment, and gaps that 
exist in the SCD population relating to HU.  The search included articles published in 
English from 2003 to 2013, using the databases: CINAHL, MEDLINE, Pub Med, 
Academic Search Premier, Cochrane clinical trials, and National Library of Medicine. 
My search also included these literatures: Sigma Theta Tau International, Nurses Science 
Quarterly, and Journal of Blood.  For inclusion criteria, the systematic review examined 
studies that included adolescents’ ages 12-18 diagnosed with sickle cell disease and are 
being currently managed with HU therapy.  Articles that identified specific barriers were 
also included.  
History of Sickle Cell Disease 
In 1910, Herrick was the first to identify sickle cell anemia when he published a 
description of peculiar and sickle-shaped red blood corpuscles in a case of a 20-year- old 
student from Grenada, West Indies. This young man was attending school in Chicago, 
where he complained of pain and was later diagnosed with severe anemia. No conclusion 
was drawn from his case until further microscopic examination of his blood work and 
other patients with similar complaints showed the same abnormal shaped cells (Herrick, 
1910).  Further investigations continued to surface regarding the shape of the corpuscles.  
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Over the years, several patients emerged with different symptomology. Doctors 
kept track of these patients and their case studies in an attempt to understand this cell 
disease.  
 In 1949, Dr. Linus Paulding and others discovered that the peculiar cell was due 
to an abnormal protein molecule. Dr. Paulding was later awarded for his work in linking 
genetic disorders and sickle cell disease together. This connection marked the birth of the 
molecular disease concept (Odievre, Verger, Silva-Pinto, & Elion, 2011). 
Impact of Sickle Cell Disease  
People with sickle cell disease experience chronic pain and acute pain episodes 
which result in frequent emergency room visits. Infection, organ damage, stroke, and 
other complications can also occur (Ballas, 2010). This disease also affects individuals 
psychologically, with affects ranging from depression, inappropriate coping strategies, 
lowered health-related quality of life, inability to perform activities of daily living, and 
role limitations, (Kofi, 2005). SCD is now recognized by world health organization 
(WHO) as a global health issue that has impacted society as a whole (Healthy People 
2020, 2013).  
The goal of Healthy people 2020 is to acknowledge that this disease has affected 
all people and all ethnicities.  Individuals who are now living longer and healthier lives 
need health care that will improve their quality of life, healthy development, and healthy 
behaviors across all stages of life.  
An average of 75,000 hospitalizations due to SCD reportedly occurred in the 
United States from 1989 through 1993. Medical expenditures during 2005 for children 
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with SCD averaged $11,702 for children with Medicaid coverage and $14,772 for 
children with employer-sponsored insurance (CDC, 2014.). The impact of SCD on the 
patient, his/her family, and society in general is significant. People with SCD are 
stereotyped with behaviors of drug dependency, as “frequent flyers” to the emergency 
department, unemployed, undereducated, and underserved (limited access to health care) 
(Ballas, 2010).  
To counteract these negative perceptions, health care providers should be 
educated regarding the disease process, life-threatening complications, available 
treatment options, and psychosocial concerns of SCD.  Most importantly, the individual 
with SCD must receive appropriate care when it comes to addressing their pain, as the 
complaint of pain is the hallmark of SCD (Ballas, 2010).  There is a need to identify the 
barriers preventing the use of HU for the management of this patient population. This 
systematic review will be used to recommend rigorous education on the effects of HU to 
patients, patient families, caregivers, and health providers.  
Risks and Benefits of Hydroxyurea 
Hydroxyurea is an antineoplastic agent originally synthesized in Germany in 
1869. Close to 50 years ago, HU was developed as an anticancer drug for the treatment of 
some types of leukemia, melanoma, myeloproliferative syndrome, and ovarian cancer 
(NIH, 2008). In 1984 HU was introduced as a treatment for sickle cell patients who meet 
the following criteria: diagnosis of HbSS or S β-thalassemia, ≥ 3 years of age, three or 
more severe vaso-occlusive pain events per year, or two episodes of acute chest 
syndrome per year (Jones et al., 2016; Sickle Cell Information Center, 2011). SCD 
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patients must take their medications, including HU, regularly in order to treat their 
disease and improve their health. Therefore, it is important to weigh the risks and benefits 
of such a treatment.  
 
The FDA (2013) stated that when a medication’s benefits outweigh its known 
risks, the agency deems it safe enough to approve it. With regards to HU, benefits 
recorded since its first testing on SCD patients include but are not limited to an increase 
in HbF, reduction in hospitalizations and pain crisis, reports of better overall HRQL, and 
better physical HRQL (Segal et al., 2008; Thornburg et al., 2011). HU has excellent 
bioavailability after oral administration and requires only once daily dosing, which 
enhances medication adherence. This benefit also makes it attractive for use in resource-
poor countries, where there may not be widespread access to facilities to perform 
laboratory monitoring (Heeney & Ware, 2009; Strouse & Heeney, 2012).  
 On the other hand, recorded risks include reducing sperm count and motility with 
resultant abnormal morphology, HU-induced dermatomyositis, mild neutropenia, mild 
thrombocytopenia, severe anemia, rash, or nail changes (Grigg, 2007; Nofal, & El-Din, 
2012). Despite the reported risks, HU has been shown to be helpful for sickle cell 
patients. The first major study of the treatment in 1995 was stopped early as it was clear 
that HU reduced the number and severity of pain episodes in patients with SCD 
compared with placebo (NIH, 2008). In 1998, HU was approved by the FDA for adults 
with SCD.  
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Although not yet approved for use on children, Heeney and Ware (2009) reported 
that HU was a powerful therapeutic drug with proven laboratory and clinical efficacy for 
children with SCD. One significant concern is the limited report on its toxicity and long 
term usage.  
An observational follow-up conducted by Steinberg et al. (2003), on individuals 
with 9 years of treatment, concluded that adult patients taking HU for frequent pain 
episodes appeared to have reduced mortality.  Similarly, to examine the risks and benefits 
of long-term HU usage, Steinberg et al. (2010) followed patients in their trial for 17.5 
years and concluded that long-term HU use is safe and might decrease mortality.  During 
the transition of HU in the treatment for SCD, there needs to be more research that will 
be carried out for appropriate management of HU use in SCD.  In obtaining more reliable 
and valid data, there have to be more patients who are using HU to develop protocols that 
will be significant with a great emphasis placed on rigorous education on the effects of 
HU to patients, family, and providers.   
Sickle Cell Disease and Quality of Life 
 The ultimate goal of health care providers is to maintain or improve the quality of 
life of individuals in general as well as, people with chronic and debilitating disease like 
SCD in particular. Traditionally, evaluating the disease burden and effect of treatment of 
SCD were mainly accomplished by determining laboratory values, calculating mortality 
data, the number of hospitalizations, and incidents of painful crisis (Charache et al., 1995; 
Platt et al., 1991; Platt et al., 1994).   
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Researchers of the last decade noted a significant increase in the development and 
use of tools to evaluate health-related quality of life (HRQOL) measures. These include 
pediatric health-related quality of life (PHRQOL) measurements or pediatric quality of 
life (PedsQL) for children and adolescents (Panepinto, Torres, & Varni, 2012).  
There are generic HRQOL tools that can be used for any disease condition and 
also disease-specific tools which are necessary for understanding a particular disease 
condition. For example, PedsQL sickle cell module (PedsQL-SCD) is used to assess 
children with SCD (Dampier et al., 2010; Panepinto et al., 2008). Since the development 
of the PedsQL sickle cell module (PedsQL-SCD), studies have been shown that the tool 
is feasible, reliable, and valid to measure HRQOL in children with SCD. A multisite 
study by Panepinto et al. (2013) of 243 pediatric patients with SCD and 313 parents to 
report on the properties of the tool, noted that the PedsQOL-SCD module has shown 
acceptable measurement qualities for use on SCD. The report also demonstrated that use 
of the tool will foster understanding of the health and well-being of children with 
(Panepinto et al. 2013) 
Definition of Terms 
For the purpose of this systematic review, the following terms were defined as: 
Health-related quality of life (HRQOL): is defined as the patient’s perception of 
his/her well-being and level of functioning compared with a perceived ideal as affected 
by his/her health. Tools that measures HRQOL are multidimensional and include 
physical, emotional, and social components, as well as school/work functioning (Darbari 
& Panepinto, 2012). 
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Hemoglobinopathies: are a group of inherited disorders in which there is 
abnormal production or structure of the hemoglobin molecule. Examples include HbC, 
HbS-C, sickle cell anemia, and different types of thalassemia (National Library of 
Medicine (NLM), 2015) 
Hydroxyurea (HU): is defined as an antineoplastic agent approved by FDA for the 
treatment of adults with sickle cell disease. It induces HbF production, increases 
erythrocyte hydration, and reduces cell adhesiveness among other things. It has also been 
reported to be a powerful therapeutic agent with proved laboratory and clinical efficacy 
for children with SCD (Heeney &Ware 2010). 
Sickle cell crisis: is defined as the beginning of painful episodes in patients with 
SCD resulting from occlusion of blood vessels by sickle-shaped red blood cells. It is 
manifested as severe pain in the extremities, back, abdomen, or chest, and is usually 
associated with fever and the passage of dark or red urine (Serjeant & Serjeant, 2001).  
Sickle Cell Disease (SCD): is defined as a chronic autosomal recessive hereditary 
disorder caused by the presence of hemoglobin S (HbS). This abnormality in the 
homozygote (SS) induces polymerization of some Hb, impeding movement blood 
circulation. It is characterized by chronic hemolytic anemia, acute vaso-occlusive crisis, 
and an increased risk for infection (Nzouakou, et al., 2010). 
Assumptions 
Upon review of the literature, my initial assumptions focused on the belief that 
SCD patients felt that HU was an experimental drug used primarily for the treatment for 
cancer patients. HU has been used for the treatment of many other diseases, including 
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SCD. The evidence has shown that there was limited research done on the long-term 
effects of the medication on SCD.  Other patients believed that the drug is too harmful, 
and some would rather take the chance of just living without the use of HU.  Because of 
the limited research completed on HU for SCD, there is little knowledge about the drug’s 
effectiveness and toxicity (Heeney and Ware (2009).  Due to the scant amount of patients 
that participated in the clinical trial for long term use of HU, there is not enough evident 
to show exactly how efficient HU use is for long-term management.  Some research 
studies that were directly focused on HU tolerance found that the treatment had positive 
results in the treatment of SCD.   In essence, many of the non-compliancy issues were 
found to be due to fertility concerns (Grigg, 2007).   
Limitations 
During the initial onset of this project, there were limited articles that supported 
the purpose of this project, which was to review and disseminate knowledge regarding 
the barriers that prevent adolescents ages 12-18 with SCD from being compliant with HU 
therapy. Despite the key terms that were used, there were only articles that referenced the 
disease itself, and not many mentioned the barriers in using HU to treat SCD.  Also, there 
were few articles on individuals between the ages of 12 and 18 using HU.  After many 
discussions and re-evaluation of the search, it was decided to expand the search to 
include adults and children diagnosed with SCD. The search was broadened to include 
many other search engines and electronic databases, both nationally and internationally, 
that had EBP about the topic. 
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Significance of the Project 
The implications for social change in HU treatment adherence by SCD patients 
include knowledge useful for this patient population, parents/guardians, care providers, 
and other researchers who are searching for direction in improving the quality of life of 
SCD patients. Also of significance would be motivating the patients’ to be engaged in 
their healthcare management. The long-term results would include increased HU usage, 
decreased painful episodes, fewer emergency room visits, and reduced patient mortality 
and morbidity. HU therapy holds the promise of improving health outcomes, thereby 
closing adherence to the treatment which is necessary to maximize its efficacy (Drotar, 
2010).  
This review yielded information that would provide increased knowledge of the 
myths and barriers that are associated with the use of HU. The objective of this review 
was to identify the myths and the barriers that are associated with HU adherence, thereby 
disseminating information that would provide patients/guardians and health care 
providers with a better understanding of those barriers.  Patients/guardians would be able 
to make an educated decision about the use of HU. Also, healthcare providers would be 
assisted in making the appropriate adjustment in the plan of care for the SCD adolescents 
who are resistant to the use of HU. Understanding the barriers preventing SCD patients 
from being compliant with HU treatment could bring about increased use of this 




SCD continues to be a complicated disease to manage, despite the innovations in 
treatment since its discovery in 1910.   Although the trajectory of the disease has 
improved, with individuals living into their forties and fifties, there are many treatment 





Section 2: Review of Scholarly Evidence 
Introduction 
In this section the background for the proposed study is presented by briefly 
summarizing the literature on HU usage in the management of SC crisis, the effect of HU 
on the HRQL of SCD patients, and the state of knowledge in HU use on children with 
SCD. The literature describing adverse reactions, effectiveness, and toxicity of HU is 
considered.  Studies exploring the concerns of the long term effects of HU are reviewed 
and critiqued. The limited studies to date of barriers preventing HU usage are evaluated, 
and the findings from this group of studies are synthesized and conclusions drawn 
regarding the gaps in knowledge that can be revealed by this systematic review. 
Additionally, this section discusses the literature search strategy, including the databases 
and libraries accessed, search engines used, the extent of the literature, and key terms 
utilized. This section further addresses the concepts, models, theories, and framework 
used and the reason for their selection. 
Literature Search Strategies  
  The search engines used were CINAHL, MEDLINE, Academic Search Premier, 
Cochrane clinical trials, Google Scholar, and National Library of Medicine databases to 
access literature on the barriers preventing adolescents ages 12-18 with sickle cell disease 
from being compliant with HU treatment. The key terms and combinations of search 
terms that were used in the review of literature include: sickle cell disease, hydroxyurea, 





The evidence-based approach that was used in implementing the systematic 
review of literature was the JNEBP known as the PET This process has three phases and 
structures the activities of EBP.  According to Newhouse, Dearholt, Poe, Pugh, & White 
(2007), the first phase is the identification of an answerable EBP question, the second 
phase is the systematic review and synthesis of both research and nonresearch evidence. 
This phase has five steps: (a) search for evidence, (b) appraise the evidence, (c) 
summarize the evidence, (d) rate the strength and quality of the evidence (see Tables 1 & 
2), and (e) develop recommendations. The final phase is translation which is to 
communicate the findings.  
 
Table 1 
JHNEBP Strength of Research Evidence Rating Scale 
 STRENGTH of the Evidence 
Level I Experimental study/randomized controlled trial (RCT) or meta-analysis of 
RCT 
Level II Quasi-experimental study 
Level III Non-experimental study, qualitative study, or meta-synthesis. 
Level IV Opinion of nationally recognized experts based on research evidence or 
expert consensus panel (systematic review, clinical practice guidelines) 
Level V Opinion of individual expert based on non-research evidence. (Includes 
case studies; literature review; organizational experience, e.g., quality 






JHNEBP Quality Rating Scale for Research Evidence 
  Quality of the Evidence 
A   High Research Consistent results with sufficient sample size, adequate 
control, and definitive conclusions; consistent 
recommendations based on extensive literature review 




Well-defined, reproducible search strategies; consistent 
results with sufficient numbers of well-defined studies; 
definitive conclusions. 
 Organizational Well-defined methods using a rigorous approach; 
consistent results with sufficient sample size; use of 
reliable and valid measures. 
 Expert Opinion Expertise is clearly evident. 
B   Good Research Reasonably consistent results, sufficient sample size, 
some control, with fairly definitive conclusions; 
reasonable, consistent recommendations based on fairly 
comprehensive literature review that includes some 
reference to scientific evidence. 
 Summative 
reviews 
Reasonably thorough and appropriate search; reasonable, 
consistent results with sufficient numbers of well-
defined studies; evaluation of strengths and limitations 
of included studies; fairly definitive conclusions. 
 Organizational Well-defined methods; reasonably consistent results 
with sufficient numbers; use of reliable and valid 
measures; reasonably consistent recommendations. 
 Expert Opinion Expertise appears to be credible. 
C   Low        
quality or 
major flaws 
Research Little evidence with inconsistent results, insufficient 
sample size, conclusions cannot be drawn. 
 Summative 
reviews 
Undefined, poorly defined, or limited search strategies; 
insufficient evidence with inconsistent results; 
conclusions cannot be drawn. 
 Organizational Undefined, or poorly defined methods; insufficient 
sample size; inconsistent results; conclusions cannot be 
drawn. 




Review of the Evidence 
Research in the area of HU and the management of sickle cell crisis (SCC) has 
evolved over the last 10 decades. Research now includes more clinical experience, 
accumulating for more than 25 years (Ware, 2010). Some studies examined the effect of 
HU on the HRQOL in individuals with SCD, outcomes reported by patients with 
hemoglobinopathies, and the difference in the HRQOL in children with SCD receiving 
HU and those that were not.   
According to Thornburg, Calatronic, and Panepinto (2013), who conducted a 
retrospective cohort study of children with SCD who had completed the HRQL, found 
that children who received HU had a higher  median (IQR) on the PedsQL than children 
who did not receive HU.  Panepinto et al. (2008) conducted a cross-sectional study to 
determine the feasibility and the validity of HRQL.  The authors used the statistical 
application of Cronbach’s alpha, which showed that the HRQL was reliable. Another 
study by Dabari and Panepinto (2012), found that HU contributed to improving the 
HRQL scores of children with SCD; in that the subjects had improvement in 
psychological coping ability.  Panepinto (2012) found that using the specific HRQL for 
patients with SCD can be useful inside and outside of the clinical setting to provide a 
better understanding of the health and well-being of patients with SCD.  
Various researchers discussed the mechanism of action of HU in relieving 
symptoms of SCC and improving the patient’s QOL. Charache et al. (1992) reported that, 
although HU is effective in the increase of HbF, it can also pose a problem in causing 
painful attacks in patients with high hematocrit (Hct).  Furthermore, Singh et al. (2010) 
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stated that gene expression is the result of increased HbF.  Also, Akinsheye et al. (2011) 
investigated different aspects of this subject.  The authors also concluded that both 
clinical and laboratory characteristics of SCA HbSS are weighted by the concentration of 
HbF. And when that happens, there is a significant increase in the percentage of HbF 
from 12.83 to 19.17% after a year’s treatment with HU.   
In another study, however, Cummings and Anie (2003) suggested that there is a 
need to investigate HU therapy patients’ QOL as well as their psychosocial status. A 
multicenter study of the effects of sickle cell conducted by Ballas et al. (2006) showed 
that oral HU reduced painful SCC by 50% and had significant results on the HQOL scale 
in the areas of daily pain and frequency. Further research by Ferster et al. (1996) noted 
the treatment of SC patients with some improved aspects of QOL that is similar to those 
reported by Ballas, et al. (2006).  The findings indicated that HU increases the production 
of HbF, thereby improving HRQOL, and may decrease the length of hospital stay for 
SCD patients.  
HU is not yet approved for use in children with SCD. Its toxicity and the lack of 
longitudinal studies concerning its effect on the adult population have been concerns. HU 
use on children was based on the effective results obtained from its use on the adult, eight 
years later in 1993. And it was reported to be effective (Ohene-Frempong, Horiuchi & 
Bulgarelli, 1993). Several studies were conducted globally and all reported low toxic 
levels, as well as the clinical and laboratory effectiveness of HU (Festa et al. 2001; 
Montalambert et al. 1999; Oury, Hoyoux, Dresse, & Chantraine, 1997). Although it has 
been shown to be effective in adults, the concerns regarding whether this medication 
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should be used in children continues to be discussed. Recent studies have reported some 
efficacy in the use of HU in children.  These few studies have shown some significance 
in increasing HbF (Braga et al., 2005). 
In 2005, an open-label uncontrolled prospective study by Braga et al., of nine 
children, to assess efficacy and safety of HU concluded that the medication was effective, 
increased HbF levels and decreased hospitalization. Another study by Smith et al. (2011) 
examined the association between HU treatment and pain intensity, analgesic use, and 
utilization in ambulatory SCD patients. Smith et al. (2011) concluded that HU treatment 
led to significant reduction in daily pain and analgesic usage in adults. More studies of 
adults and children are needed to provide more information for providers to make their 
decision concerning HU usage.   
Few studies on managing SCD with HU have been supportive of the treatment. 
Some studies reported no adverse reaction (Al-Nood, Al-Khawlani, & Al-Akwa, 2011; 
Singh et al., 2010) while others recorded effectiveness with some side effects (Grigg, 
2007; Lanzkron et al., 2008; Stouse et al., 2008).  
There continues to be concern related to the efficacy and safety of HU. This 
concern exists among patients, health care providers, and researchers. Many researchers 
are still not sure about HU use or its long-term effects in the management for SCD 
patients.  There seems to be some concern with regards to the seriousness of the side 
effects associated with the drug.  One study reported that the side effects were so serious 
that the research had to be held until laboratory results were stabilized, and labs such as 
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those for thrombocytopenia and neutropenia were stabilized before restarting the dose 
(Jones et al., 2016).   
In another study of 15 patients by Yates et al. (2013), HU was effective in 
increasing the HbF and resulted in a significant decrease in episodes of chest syndrome, 
pain, and hospitalizations. However, there were significant side effects recorded, 
including; thrombocytopenia, which resulted in treatment being discontinued for one 
patient. Nonetheless, the study concluded with suggestions that HU is efficacious and 
safe for long term use in children with SCD.  
In regards to fertility, the fear of reduced sperm count and abnormal pregnancy 
are of great concern to patients of childbearing age, and there is evidence to confirm their 
fears. Grigg (2007) carried out a retrospective review of four adult men who had semen 
analysis while on hydroxyurea.  Three cases upon cessation of treatment concluded that 
one-out of the three cases had azoospermia, however, spermatogenesis returned after 
treatment had stopped. However, the other two cases have been reported to show 
impairment of sperm morphology and motility which continues to be of concern to both 
patients and researchers.  
As a result of his observation he recommends that men planning to have long 
treatment of HU should: (a) sperm bank before starting treatment, (b) monitor sperm 
count annually, and (c) use contraception if not azoospermic for at least three months if 
sexually active with a fertile partner during HU therapy( Grigg, 2007). A second 
experiment on effect of HU on male fertility was conducted by Jones et al. (2009) to 
determine if the adult male transgenic SC mouse exhibits the patterns of reproductive 
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endpoints (hypogonadism) characteristic of men with SCD and also whether HU 
aggravates this condition. The experiment concluded that HU treatment exacerbates the 
already SCD-induced hypogonadism to gonadal failure.   
Another rare adverse reaction has also been reported.  Nofal and El-Din (2012) 
reported a case study of a 68-year-old woman on HU treatment for chronic myeloid 
leukemia diagnosed 9 years prior. The patient’s symptoms were reported to be gradual, 
with a non-pruritic erythematous rash on the dorsum of the hands and graduated to 
extremely disabling painful ulcers that interfered with walking. The authors reported that 
the dermatitis could be induced by different medications, but HU is the most commonly 
implicated.   
Summary and Conclusion 
To summarize, SCD is one of the hemoglobinopathies that has an effect on the Hb 
in the body.   As a result, the entire body is affected, due to anemia and hypoxia, causing 
painful episodes.  There have been many innovations in the treatment of SCD; however, 
hospital admission and fatality still continue to be a problem for SCD patients.  In 1998, 
HU was approved by the FDA, and researchers hoped that it would improve the QOL for 
the SCD patients.   
Data showed that the use of this medication would increase the HbF of the SCD 
patient, thereby decreasing painful SCC, acute chest syndrome, mortality and morbidity.  
Despite these findings, the report has shown that patients with SCD are not adherent to or 
compliant with HU use (Yates et al., 2013). There continues to be a very low percentage 
of patients who adhere to taking HU.  Other reports show that patients are not well 
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informed about the risks and benefits of HU. Thus, fear and confusion continue to be 
additional barriers to taking this medication (Lebensburger et al., 2013).  
 
Due to the lack of education and fear of adherence to HU, advanced nurses are in 
line to educate the SCD population on how to be compliant with HU.  Thereby nurses 
will make an impact on the proper utility of HU globally, thus improving patients’ QOL, 
as well as reducing co-morbidity in SCD through education and positive EBP.  As an 
advanced nurse practitioner, this writer is passionate about the well fair and the care of 
the SCD population.  SCD continues to be a disease where there is a vast disparity in 
health care, education and research. It is my view that this gap in treatment for this 
population needs much more to be done.   Therefore, this writer will continue to be a 
force that will assist in improving the health and education of SCD patients. 
As this relatively new drug is monitored more closely to note its efficiency and 
efficacy for the treatment of SCD; then the evidence will show how HU will improve the 
overall lives of SCD patients, thus the gaps that were identified in the literature, regarding 
the barriers will be reported in the method section. The findings will be disseminated to 
the SCD community which will assist in improving the trust relationship among patients 
and health care providers.  As a result, there hopes to be an increase in the use of HU 
among SCD patients.  This systematic review provided evidence needed to connect the 
gaps in the literature and the methods by illustrating what the findings revealed.   
26 
 
Section 3: Approach/Project Design and Methodology 
Introduction 
The purpose of this project was to carry out a systematic review of evidence to 
determine the barriers preventing adolescents ages 12 – 18 with SCD from complying 
with HU treatment. The major parts of this section are: (a) the EBP guideline used for the 
project implementation and rationale for using it, (b) the method used to search for 
evidence including search engines used, the process utilized for the selection of evidence 
that met criteria, and (c) how selected studies were evaluated for strength and quality. 
Institutional Review Board 
A systematic review of literature is used to identify, appraise, and synthesize 
studies to answer a specific clinical question and draw a conclusion about the data 
gathered (Melnyk & Fineout-Overholt, 2011). The reasons a literature review may be 
performed include but are not limited to: discovering what is already known and new 
knowledge about a topic, as well as assisting in designing new research studies (Oermann 
& Hays, 2011). A systematic review is a research study that requires an Institutional 
Review Board (IRB) approval. The IRB for Walden University consists of staff and 
faculty members from each of the major research areas, and they are responsible for 
making sure that all of the University’s research studies comply with the university’s 
ethical standards as wells as federal regulations. It is a requirement of all Walden students 
and faculty members conducting research studies involving the collection of data and 
analysis to request an IRB approval (Walden University, n.d.). The IRB approval for this 
DNP project was assigned the following number: 09-24-15-0336323. 
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Approach and Rationale 
The evidence-based practice guideline that was used for the implementation of 
this systematic review was the JHNEBP model simply described as the PET process. 
There are three parts and several steps to this EBP process.  The steps include but are not 
limited to: (a) identify an EBP question, (b) extensively search for evidence, appraise the 
evidence, summarize the evidence, rate the strength of the evidence, and (c) develop 
recommendation for change based on the strength of the evidence (Newhouse, Dearholt, 
Poe, Pugh, & White, 2007).The aim of this approach was to provide the best possible 
research evidence on the existing knowledge of the barriers to HU use; thus, closing the 
gaps that exist in the management of this disease in the SCD population. 
Defining Structured Question 
The identification of a practice question, issue, or concern begins the process of 
translating evidence into practice. According to Newhouse, Dearholt, Poe, Pugh, & White 
(2007), this is one of the crucial steps, because the rest of the process is driven by how 
the question is asked. According to Newhouse et al. (2007), several steps are included in 
applying the best evidence to practice and using the PICO format. This format focuses on 
the search and saves an undue amount of time in searching the literature for an answer to 
the question. To yield the most relevant information and best evidence for this project, 
the PICO approach was utilized to identify a specific EBP question. Using the PICO 
format clarified and organized the following: 




2. I – issue of interest: compliance with hydroxyurea. 
 
3. C – Comparison of interest: noncompliance with treatment regimen 
4. O– Outcomes of interest: improvement of HU use and the barriers that 
prevent usage described in the literature. 
 
Method 
A systematic and comprehensive search for evidence was performed using the 
search engines of CINAHL, MEDLINE, OVID, Academic search Premier, Cochrane 
clinical trials, and Cochrane database of the systematic review from 2003 to 2013.  The 
period covered ten years of relevant literature on the topic, and only articles published in 
English were identified.  The following search terms or a combination of words were 
used: hydroxyurea, sickle cell disease, hydroxyurea therapy, sickle cell crisis, barriers to 
hydroxyurea therapy, sickle cell disease, sickle cell management and hydroxyurea.  The 
text words contained in title and abstract, as well as in the index terms used for the 
description of the article were analyzed. Using all identified keywords and index terms, a 
second search was done across all databases. All studies that met inclusion criteria were 
retrieved for review and analysis. The intent of this review was to identify available 
evidence on barriers that prevent SCD patients from adhering to HU therapy. 
Inclusion Criteria 
This systematic review examined studies that included adolescents’ ages 12-18 
years old, who were diagnosed with SCD and were being managed with HU therapy.  




Articles that included title, keywords, or abstracts that were vague and not related 
to the research question were excluded. 
Selection 
The goal of this search approach was to retrieve both published and unpublished 
studies. Using a three-step strategy, an initial search of CINAHL and MEDLINE was 
done to form a list of keywords, next was the analysis of the text words contained in title 
and abstract, as well as in the index terms used for the description of the article. Using all 
identified keywords and index terms, a second search was done across all included 
databases. All studies that met inclusion criteria were retrieved for review. Finally, the 
reference list of all identified reports and articles were searched for additional studies 
The initial search located N=19,932 potential relevant articles.  The articles that 
had the key words HU and SCD (N=99), based on the title, or abstracts were reviewed. 
There were (N=31) articles that were specific to different types of SCD, including the 
thalassemias, minor and major as well as sickle cell disease Hgb C. Finally, there were 
only, (N=5) articles that reported on barriers specific to HU use: from the providers’, 
patients’, and families’ perspectives. These five articles have shown the different kinds of 
barriers specific to the use of HU and are illustrated in Table 4. The remaining 26 articles 
were vague and did not identify the effects of HU for SCD. These articles only briefly 
mentioned HU as in innovative treatment, but failed to report any significant findings as 
they relate to the efficacy and safety of the drug. As a result, these articles did not meet 
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the inclusion criteria. The results of the electronic literature search and strategy are shown 
in Table 3 and Figure 2. 
Summary 
The utilization of the JHNEBP evidence rating scale for strength and quality 
during the implementation of the systematic review provided a methodology to analyze 
the literature. This EBP guideline also helped to acquire a better understanding of the 
barriers preventing SC patients from complying with HU. The extensive search yielded 
only five articles for synthesis. This systematic review of the literature did not require 
human subjects. As such, the IRB application that was sought through Walden University 
IRB was only used as a requirement for program completion. 
Table 3 




















SCD 1,399   4,721 0 1,935 30 0 
HU    499 10,388 0    708 4 0 
SCD and HU 
therapy 
     13         65 2      31 0 0 
SC Crisis and 
HU therapy 
       1           1 1        2 0 0 
Barriers to 
HU and SCD 
       1           1 0        4 0 0 
SC Mgt. and 
HU 
     22        97 0        7 0 0 
 





























Abstracts retrieved for 
detailed examination 
N=99 
Articles assessed in 
full 
Articles assessed for 
methodological 
quality 
Articles included in 
systematic review 
N=5 
Articles omitted based 
on title, keyword, and 
abstract 
Articles excluded after 
evaluation of abstract 
N=68 
Articles excluded after 




Section 4: Discussions and Implications 
Introduction 
The overall purpose of this systematic review was to identify the barriers that 
have prevented adolescents ages 12-18 with sickle cell disease from being compliant with 
HU therapy.  Such barriers have been reported to stem from the patient, health care 
providers, and the system; financing, limited access to care, and problems of transitioning 
from pediatric to adult care (Heeney, 2012).  Therefore, these multidimensional concerns 
that pose the current challenges to the SCD population need to be investigated. This 
project was guided by the question: what are the barriers that prevent patients with SCD 
from being compliant with HU?  The evidence was evaluated using the JHNEBP 
evidence-based rating scale. This tool is described in Section 3, which established the 
criteria on which to base the strength and the quality of the studies reviewed. 
 
Findings 
 The identified articles were evaluated with the JHNEBP guidelines for strength 
and quality. This reference provided a framework for analyzing EBP, in which specific 
indicators provided rating scales and the quality of the tool. This format provided levels 
of the strength of the evidence. This prioritized the research based on its rigor, systematic 
approaches, and the type of clinical trials conducted. This kind of leveling differentiates 
between experimental studies and nonexperimental studies, such as cohort studies, case 





JHNEBP Evidence Rating Scales: Strength and Quality of the Evidence 
STRENGTH 
& QUALITY 





Enrollment in the 
Context of Sickle 




A qualitative  phenomenology 
Exploratory  study design 
Sample size: N=6-8: average age 
(31-56 year).  All participants were 
African- Americans.    
 
Three main themes 
emerged as related to 
barriers: 
1-General Barriers: 
Practical issues cost time; 
parents rather to take the 
meds than the child. 
2- Randomized trials 
Medications vs. placebo 
How are patients 
randomized 
3- HU 
 Too costly ] 
Long-term effect  
Acute side effects. 
. Each focus group 
was intended to 
include eight 
participants; 
however there was 
reduction in 
attendance which 
had reduced the 
diversity of the 
sample population 
and introducing the 
possibility of 
response bias. The 
demographic data 
was collected after 
informed consent, so 
differences in the 
parent population 
were not known.  
 
 
4/Good Hydroxyurea for 










A recommended  guideline  
N = 227 
The evidence showed 
that HU reduce painful 
events and 
hospitalization in 
children of all ages with 
HbSS. The evidence is 
not sufficient enough to 
convince the authors to 
start HU in all children 
with SCD. 
The United States 
was one of the only 
countries that carried 
out a large clinical 
trial of HU in 
pediatric SCD which 
represent >1% of the 
global burden of 
SCD 







Observational data design 
N= 500 
There need to be means 
of how healthcare 
providers can improve 
the adherence of HU 
usage. There has to be 
appropriate monitoring 
and support given due to 
the perceive complication 
of HU. Healthcare 
providers have to provide 
accurate information to 
patients and families who 
are interested in starting 
on HU therapy. 
A limitation of the 
findings is from 
expert opinion who 
has observed 
hundreds of patients 
with SCD, who 
participate in the HU 
trial. However, 
needed randomized 
clinical trials to be 
done.to provide 
statistical evidence 
on the efficacy and 
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STUDY DESIGN AND SAMPLE RESULTS LIMITATIONS 
4/Good Provider Barriers 
to Hydroxyurea 
Use in Adults 
with Sickle Cell 
Disease: A 





Lanzkron, et al., 
2008 
 
A survey design: a 45-item 
questionnaire. 
Sample size: N-148 names of 
people, including, nurse, 
practitioners, nurses and others.   
Ninety-four percent of 
patients’ with SCD had 
read or heard about the 
recommendation of using 
HU. Providers had many 
concerns regarding 
prescribing HU.  Such as 
patients not being 
compliant with needed 
blood tests. Not being 
compliant with taking 
HU. Another concern by 
physicians’ is that 
patients do not have 
enough information on 
HU, also the concern 
about carcinogenic 
effects.  
Low response rate. 
There was a 47% 
response rate, which 
is consistent with 
other surveys. 
Another limitation is 
the physicians who 
were selected to 
participate in the 
study. In that, they 
do not represent the 
providers that 





















N=506 Telephone contacts 
The use of HU needs to 
be better advertised and 
disseminated within the 
SC communities. Further 
tools need to be 
developed to educate the 
community at large. 
Evidence showed that 
barriers to wider use of 
HU include physician 
concerns about the 
carcinogenic potential of 




adverse effects, concern 
about the lack of 
contraceptive use, and 
patient compliance. 
The survey was 
limited to Florida 
and North Carolina 
and as such not an 
adequate 





There has been limited research conducted on HU therapy for managing SCD, 
and the barriers to its use. However, published evidence supports the argument that HU 
induces the production of HbF, decreases the hospitalization rate, and decreases the 
infection rate of adolescents with SCD. The lack of data concerning adults taking this 
therapy or the long-term effects of this treatment on children is a major concern. It will be 
difficult to arrive at a conclusion because of limited evidence. 
Two of the five articles included in this review arrived at final decisions based on 
a minuscule number of studies carried out in this field. The researchers, Lebensburger et 
al. (2013), had some concerns when using African-Americans (AAs) in research studies.  
Focus group attendance was low, reducing diversity and addressing the common beliefs 
regarding how AAs see the participation in research. The report of how AAs feel about 
participating was very obvious.  The study identified three main themes related to barriers 
to clinical trial enrollment: (a) general barriers to health related research; practical issues, 
emotional issues, mistrust of doctors or studies, (b) concerns of trial design; 
randomization, and (c) concerns of HU;  long term unknown risks. Despite the small 
number of participants, focus group n=3; parents/guardian n=14, saturation was 
achieved, leading to significant contributions to the development of strategies for the 
recruitment of AA children in clinical studies (Lebensburger, et al. 2013).   
Ware (2010), who reported on HU use for young children with SCD, had15 years 
of experience with the use of HU for SCD patients.  He observed hundreds of patients 
with SCD who participated in the HU trial. The study identified barriers to the use of HU 
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to include provider’s inadequate knowledge about HU, patients and family not offered 
treatment, and when offered refuse due to unrealistic fears. Data from randomized 
controlled trials (RCT) will be needed to provide statistical evidence of the efficacy and 
toxicity of HU in the management of SCD.  
Additionally, the survey done by Zumberg et al. (2005) identified barriers to the 
broader use of HU, which include: (a) physicians’ concern about carcinogenic potential, 
(b) doubts about HU effectiveness, (c) perceived patient apprehension about adverse 
effects, (d) concerns about the lack of contraceptive use, and (e) non-compliance of 
patients. The survey was limited to Florida and North Carolina, and as such was not 
sufficient representation of the sickle cell population. Zumber et al. (2005) addressed the 
risks of HU use that cannot be disregarded, but rather provide the consumers with needed 
information necessary to make the best decisions. Zumber et al. reported that a decrease 
in the neutrophil count is associated with HU which exposes the patient to infection. 
Strouse and Heeney (2012) recommended treatment guidelines for the use of HU 
in treating children with SCD. Their recommendations were based on the evidence that 
HU reduces painful events and hospitalization in children of all ages with HbSS. The 
evidence is not sufficient enough to convince the authors to start HU in all children with 
SCD. Because limited research was done for children with SCD, little is known about the 
efficacy and the complete interactions of HU. However, active research and investigation 
continue in order to validate the effects of HU use in children with SCD (Lanzkron et al. 
2008).  Poor adherence was identified as the primary reason that HU therapy is 
ineffective in the treatment of children with SCD.  Lack of knowledge about HU 
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continues to be a challenge.  The review of evidence illustrates that there is a need for 
future research on the use of HU.  
Implications 
 I have demonstrated that research is limited in the area of HU therapy and 
the non-compliance of therapy among adolescents ages 12 – 18 with SCD. The reason for 
this is multifaceted. According to Heeney (2012), some reasons for the nonadherence are 
systemic barriers, patient and family/caregiver barriers, and provider barriers. The care of 
this patient population cannot be carried out adequately until the reasons related to the 
limited usage of HU are addressed.  
Further research needs to address the barriers that are preventing the SCD patients 
to adhere to the HU medical regimen.  Several studies (Ballas et al., 2006; Dabari & 
Panepinto, 2012; Lanzkron et al., 2008; Platt, 2008)) indicate that the use of HU has been 
beneficial in the decrease of painful sickle cell crises when HU is maintained.   
Therefore, it would be beneficial for nurses to identify the causative agents involved in 
decreased use of HU in SCD patients. 
Strengths and Limitations of the Project 
Strengths 
This DNP project had several strengths. First, the project addressed a major 
concern in the SCD community. Research has shown HU to be beneficial for SCD 
patients, but usage remains limited; uncovering the barriers to the minimal use is needed.  
Secondly, the project is a systematic review of the literature and I will use the outcome to 
recommend an educational program that nurses can utilize in their practices to provide 
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evidence-based care. Thirdly, identifying the barriers to HU usage allows for an 
understanding of the different types of barriers to HU use that originate with patients, 
patient relatives, system; financing, health care disparity, and providers. 
Limitations 
 This project had its limitations. The review only included articles written in the 
English language.  This was a limitation to the study because this could have eliminated 
other important research studies that were done in other languages. Another limitation of 
note is the fact that all articles were retrieved only from online resources and as such 
credible studies in paper format could have possibly been left out. Restricting the study to 
10 year period is also a limitation, as several articles that could have illuminated the 
barriers to HU use were excluded. Focusing on the patient population of interest 
(adolescents’ ages 12-18) with SCD could also have eliminated studies focusing on adults 
and children.   
Analysis of Self 
Scholar 
Before undertaking this project, I did not know how encompassing and 
overwhelming a systematic review can be. Retrospectively, I underestimated the project. 
However, the DNP curriculum at Walden prepared me with the skills needed to 
understand and navigate any unforeseen obstacles and challenges that I encountered. The 
experience of this endeavor has taught me to have a clear goal and a vision of the 
outcome, and what it will take to reach the target. According to American Association of 
Colleges of Nursing [AACN] (2013), scholarship and research are the hallmarks of 
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doctoral education. My DNP project epitomizes the scholarship of discovery and 
integration which, according to Boyer (1990), reflects the investigative and synthesizing 
traditions of the academic life. This competency is Essential III of the eight DNP 
Essentials ([AACN], 2013, p.11). 
Practitioner 
This project has increased my knowledge of SCD in ways I never imagined. 
Working on this topic area for over two years has given me confidence and the ease to 
talk about many aspects of SCD. I am enthusiastic about discussing the new knowledge 
with my colleagues. I hope to arouse their interest in this patient population and the 
management of their condition. This project has improved my ability to synthesize and 
critique the literature faster than before this study.  
Project Developer 
This systematic review of evidence afforded me the opportunity to identify the 
different barriers to HU use.  Such barriers ranges from institutional involvement, 
patient/family/caregiver fears’, and healthcare providers limited knowledge regarding the 
outcome of HU use.  With this information, I will recommend rigorous education 
programs that will increase professional knowledge and awareness of this practice 
problem. Additionally, I would like the sickle cell disease population to realize the need 
and possible benefits of incorporating HU therapy into their disease management. Adding 
this promising medication to their treatment regimen can reduce pain crises, infections, 




Despite the significant findings of the effects of HU, many barriers to treatment 
still exist. Some restrictions prevent patients from achieving the effects of a drug that 
may have increased benefits: decrease crises pain, reduce emergency department visits, 
increase HbF levels and improve polymerization of the cells, causing less sticking of 
cells.  Despite limited use in children ages < 3, the review of literature also revealed that 
HU may contribute to the improvement of HRQL of adolescents with SCD. Due to 
morbidity and mortality associated with SCD, efforts to improve their QOL are of great 
concerns. The minimal usage of HU continues to be a gap that was identified by this 
review.  Further research needs to be conducted to better understand the barriers that 
prevent the SCD patients from using HU.  
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Section 5: Scholarly Product 
Project Dissemination 
According to Oermann and Hays (2011), the dissemination of research findings 
that have examined the different interventions accessible to the health care system, 
support EBP endeavors and are effective means to build healthcare knowledge.  This 
project was undertaken to review and synthesize all evidence available on the barriers 
preventing adolescents ages 12 – 18 with SCD from being compliant with HU. The SCD 
population could benefit from this review as the findings from this project could further 
promote best practices or change of practice that this patient population needs. To bring 
about change with this systematic review of the literature, I must disseminate the result to 
the SCD communities, caregivers, and providers nationally and internationally through 
publication, poster presentations, manuscripts, etc. 
 Subsequently, I intend to circulate this research study through poster 
presentations and publications. The reason for this choice is that poster presentations 
have the potential to reach a broader audience that could easily reach sickle cell patients, 
their families, health care practitioners, and providers in the Bronx,  New York, the 
tristate area, as well as nationally and internationally. The publication of the results of 
this systematic review could be used to improve the care of SCD patients. Education 
programs addressing the identified barriers can be implemented that will change 
behaviors and improve the knowledge base of the community as a whole.    
Due to the findings of this systematic review, the evidence has shown that many 
unanswered questions exist on the management of SCD with HU.  Many patients 
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continue to be resistant to taking HU, despite all of the comprehensive research that has 
been done to show its effectiveness in cases of SCD.  Comprehensive education must be 
provided for all ages and all cases of SCD patients to support the impact that HU has on 
SCD patients. 
Education must be geared towards identifying the barriers and clearing up the 
myths that exists for HU.  By providing mass media of information on HU, this will 
decrease the barriers and improve the compliance rates of HU.  Education should exist on 
the risks and benefits of HU, as well as on the current research and the findings from 
experts regarding the effectiveness of HU.  Obtaining feedback from the audience; 
patients, their families, and health care providers after an education session is essential, in 
that further clarification can be made to decrease the fear of taking HU.  I will make 
additional efforts to provide education in community based organizations with people 
who are afflicted with SCD, as well as churches where there is a high incidence of SCD 
within the community.  Brochures and pamphlets on the effectiveness of HU will also be 
disseminated throughout the communities with high incidence of SCD. Future 
development of educational applications for smartphones and tablets will also be 
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